What was reported
Jiahui's public article describes Joshua as a New Zealander diagnosed with multiple myeloma in 2008, later relapsing and seeking BCMA CAR-T treatment in Shanghai in 2023. The story reports that he was discharged within about two weeks after treatment monitoring. Individual outcomes vary and must not be generalized.
Why international patients notice stories like this
CAR-T availability, trial history, product eligibility, hospitalization requirements, infection-risk monitoring, translation, and post-discharge follow-up are all practical barriers. A public case helps patients understand the planning work behind a medical travel decision.
How to use this information
Patients exploring similar options should prepare pathology, marrow reports, cytogenetics, treatment history, imaging, medication lists, infection history, performance status, and a concise clinical timeline before asking whether a Chinese center can review the case.